MedTrace Logo

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

NCT02490488 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2020-12-08

No results posted yet for this study

Summary

The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.

Conditions

Interventions

DRUG

Masitinib

DRUG

Gemcitabine

DRUG

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Julien Grenier, Dr · AB Science

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Algeria
  • France
  • Russia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490488 on ClinicalTrials.gov